Fibrobiologics, Common Stock Stock Last Dividend Paid
| FBLG Stock | 2.15 0.01 0.46% |
FibroBiologics, Common Stock fundamentals help investors to digest information that contributes to FibroBiologics, Common's financial success or failures. It also enables traders to predict the movement of FibroBiologics, Stock. The fundamental analysis module provides a way to measure FibroBiologics, Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroBiologics, Common stock.
FibroBiologics, | Last Dividend Paid |
FibroBiologics, Common Stock Company Last Dividend Paid Analysis
FibroBiologics, Common's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
FibroBiologics, Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for FibroBiologics, Common is extremely important. It helps to project a fair market value of FibroBiologics, Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since FibroBiologics, Common's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of FibroBiologics, Common's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of FibroBiologics, Common's interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, FibroBiologics, Common Stock has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
FibroBiologics, Common ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, FibroBiologics, Common's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to FibroBiologics, Common's managers, analysts, and investors.Environmental | Governance | Social |
FibroBiologics, Fundamentals
| Return On Equity | -2.68 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 68.6 M | ||||
| Shares Outstanding | 34.66 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 15.83 % | ||||
| Number Of Shares Shorted | 2.7 M | ||||
| Price To Book | 27.35 X | ||||
| EBITDA | (15.9 M) | ||||
| Net Income | (16.48 M) | ||||
| Total Debt | 1.75 M | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Short Ratio | 13.56 X | ||||
| Earnings Per Share | (0.55) X | ||||
| Target Price | 12.75 | ||||
| Number Of Employees | 10 | ||||
| Market Capitalization | 74.86 M | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (24.36 M) | ||||
| Working Capital | 32 K | ||||
| Net Asset | 11.82 M |
About FibroBiologics, Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroBiologics, Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroBiologics, Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroBiologics, Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out FibroBiologics, Common Piotroski F Score and FibroBiologics, Common Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.